Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation
- 3 September 2013
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 62 (10), 900-908
- https://doi.org/10.1016/j.jacc.2013.05.042
Abstract
No abstract availableFunding Information
- Boehringer-Ingelheim
- AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Pfizer, Janssen, and sanofi-aventis
- Boehringer-Ingelheim
- Boehringer-Ingelheim
This publication has 18 references indexed in Scilit:
- Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are UnsuitableAnnals of Internal Medicine, 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of DabigatranThe New England Journal of Medicine, 2011
- Newly Identified Events in the RE-LY TrialThe New England Journal of Medicine, 2010
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranAmerican Heart Journal, 2009
- Effect of Clopidogrel Added to Aspirin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialThe Lancet, 2006
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976